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Impaired driving due to drug use is a growing problem worldwide; estimates show that
18–23.5% of fatal accidents, and up to 34% of injury accidents may be caused by
drivers under the influence of drugs (Drummer et al., 2003; Walsh et al., 2004; NHTSA,
2010). Furthermore, at any given time, up to 16% of drivers may be using drugs that can
impair one’s driving abilities (NHTSA, 2009). Currently, drug recognition experts (DREs;
law enforcement officers with specialized training to identify drugged driving), have the
most difficult time with identifying drivers potentially impaired on central nervous system
(CNS) depressants (Smith et al., 2002). The fact that the use of benzodiazepines, a type
of CNS depressant, is also associated with the greatest likelihood of causing accidents
(Dassanayake et al., 2011), further emphasizes the need to improve research tools in
this area which can facilitate the refinement of, or additions to, current assessments
of impaired driving. Our laboratories collaborated to evaluate both the behavioral and
neurophysiological effects of a benzodiazepine, alprazolam, in a driving simulation
(miniSimTM). This drive was combined with a neurocognitive assessment utilizing time
synched neurophysiology (electroencephalography, ECG). While the behavioral effects
of benzodiazepines are well characterized (Rapoport et al., 2009), we hypothesized
that, with the addition of real-time neurophysiology and the utilization of simulation and
neurocognitive assessment, we could find objective assessments of drug impairment
that could improve the detection capabilities of DREs. Our analyses revealed that (1)
specific driving conditions were significantly more difficult for benzodiazepine impaired
drivers and (2) the neurocognitive tasks’ metrics were able to classify “impaired” vs.
“unimpaired” with up to 80% accuracy based on lane position deviation and lane
departures. While this work requires replication in larger studies, our results not only
identified criteria that could potentially improve the identification of benzodiazepine
intoxication by DREs, but also demonstrated the promise for future studies using this
approach to improve upon current, real-world assessments of impaired driving.
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INTRODUCTION
Driving while impaired is illegal in most countries worldwide
due to the public health and safety risks associated with this
behavior. Such impairment is often illegal regardless of whether it
is due to alcohol, illegal/recreational drugs, or prescription drugs.
Despite its illegality, the 2013 National Survey on Drug Use and
Health found that 3.8% of those aged 12 or older, an estimated 9.9
million people, self-reported driving under the inﬂuence of illicit
drugs within the past year (SAMHSA, 2014). In addition to legal
penalties, drugged driving comes with severe health risks as well.
While the rate of fatal crashes due to drunk driving has generally
been declining over the years (NHTSA, 2013), nonalcoholic-
drugged driving-related fatalities have increased from 16.6% in
1999 to 28.3% in 2010 (Brady and Li, 2014). Rates of accidents,
in general, have shown similar trends as well. In one study of
322 vehicular accident victims admitted to a trauma center in
Maryland, urinalysis and plasma results showed that 15.8% of
these victims tested positive for alcohol only, 9.9% tested positive
for both alcohol and drugs, while an alarming 33.5% tested
positive for drugs only (Walsh et al., 2004).
Although the risk of being involved in a fatal car accident
is greatly increased by drug use (Li et al., 2013), the level
of risk and prevalence is not the same across all drug types.
Central nervous system (CNS) depressants, as compared to
stimulants, narcotics, and cannabis, are associated with the
greatest risk (Li et al., 2013). A 2007 National Highway Traﬃc
Safety Administration study randomly selected drivers at traﬃc
stops across the US during several time points throughout the
day and found that benzodiazepines were one of the most
commonly encountered drugs being used in day-time drivers
(Lacey et al., 2009). These data are consistent with multiple
studies and one meta-analysis showing that benzodiazepines are
associated with 60–80% increased risk for vehicular accidents
(Dassanayake et al., 2011). Furthermore, drivers who are at fault
in an accident are 40% more likely to have been under the
inﬂuence of benzodiazepines than those who are not at fault
(Dassanayake et al., 2011).
Due to the public health risks associated with driving
under the inﬂuence of benzodiazepines, objective assessments
of the cognitive, behavioral, and physiological correlates of such
impairments are needed. While alcohol related impairments are
predictable, and correlated to breath alcohol content (BrAC), a
recent review of the relationship between plasma concentrations
of benzodiazepines and driving performance did not ﬁnd a clear
dose–response relationship (Verster and Roth, 2013). Therefore,
detection of impairment due to other substances has relied
on alternative assessments performed by Drug Recognition
Experts (DREs). A DRE evaluation includes observations of
many factors, including (but not limited to): physical appearance,
driving behaviors, vital signs, psychomotor functioning, etc
(Talpins and Hayes, 2004). These evaluations have proven to be
highly successful in detecting driving impairments due to drug
intoxication in general, yet, out of all drug classiﬁcations, with
the exclusion of alcohol, CNS depressants are the least likely
(41.7%) to be accurately recognized by DREs (Smith et al., 2002).
Further research on correlates of benzodiazepine impairments is
needed to validate the existing criteria and provide additional
signs for DREs to rely on to increase their accuracy in drug
speciﬁcity. Alternative research methods and tools may be
necessary to facilitate such investigations. In particular, the
utilization of a cognitive and physiological assessment with time-
synced neurocognitive tasks and electroencephalography (EEG)
may prove to be a successful approach toward meeting this goal.
Research has shown promise for the utilization of cognitive
and behavioral performance for such an assessment. In regards to
cognitive task performance, benzodiazepines decrease alertness
(Verster et al., 2002; Barker et al., 2004), increase reaction times
(Fernández-Guardiola et al., 1984; Suzuki et al., 1995; Münte
et al., 1996; Verster et al., 2002; Barker et al., 2004; Snyder et al.,
2005; Leufkens et al., 2007), impair vigilance (Kožena et al., 1995),
and impair various memory functions such as verbal and working
memory (Linnoila et al., 1990; Rush and Griﬃths, 1997; Verster
et al., 2002; Barker et al., 2004; Snyder et al., 2005; Leufkens et al.,
2007). These eﬀects are dose-dependent. For example, a 0.5 mg
dose of the benzodiazepine, alprazolam, signiﬁcantly slowed
reaction times on simple attention tasks (Snyder et al., 2005).
A 1.0 mg dose also slowed reaction times on simple attention
tasks and additionally decreased accuracy on tasks assessing
executive functions and learning, and increased reaction times
on executive and psychomotor tasks (Snyder et al., 2005). In
addition to impairing cognitive function, benzodiazepines can
have adverse eﬀects on motor control (Verster et al., 2002; Barker
et al., 2004) and psychomotor functioning (Linnoila et al., 1990;
Rush and Griﬃths, 1997; Riba et al., 2001; Barker et al., 2004;
Snyder et al., 2005). Taken together, these data suggests that this
class of drug may impair various driving-related skills as driving
requires the coordination of both cognitive and motor skills. In
fact, studies have conﬁrmed that benzodiazepine use is directly
associated with driving impairments related to control of lateral
position within the lane or completely crossing into adjacent
lanes or shoulders (O’Hanlon et al., 1982; Van Laar et al., 1992,
2001; Bocca et al., 1999; Verster et al., 2002; Leufkens et al.,
2007), speed control (Van Laar et al., 1992; Verster et al., 2002;
Staner et al., 2005), and steering (Smiley and Moskowitz, 1986).
Use of this drug has also been shown to negatively impact one’s
abilities to assess the surrounding environment (Verster et al.,
2002; Leufkens et al., 2007; Dassanayake et al., 2011) and to slow
reaction times related to driving performance (Kuitunen, 1994;
Bocca et al., 1999; Vanakoski et al., 2000; Leufkens et al., 2007;
Dassanayake et al., 2011).
EEG has also been utilized to measure the neurocognitive
eﬀects of benzodiazepines and driving. Benzodiazepines can
aﬀect several EEG power spectral density bandwidths linked
to attention and internal processing (Buchsbaum et al., 1985;
Harmony et al., 1996; Eoh et al., 2005). Research has shown
benzodiazepines to be related to increases in Delta (1–3 Hz)
in the bilateral frontal–temporal and temporal–occipital regions
(Staner et al., 2005). Such increases in Delta, as well as Theta
(3–7 Hz), have been positively correlated with fatigue while
driving (Lal and Craig, 2002; Campagne et al., 2004), and
could possibly serve as an indicator of benzodiazepine-related
driving impairment. Benzodiazepines also decrease Alpha (8–
13 Hz) band activity in the frontal, temporal, and occipital
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regions (Buchsbaum et al., 1985; Bond et al., 1992; Staner et al.,
2005). Suppression of Alpha activity can be indicative of task-
related increases in cognitive demand (Klimesch, 1999; Eoh et al.,
2005) and has even been speciﬁcally linked to driving; easier
simulator courses produce higher levels of Alpha than more
diﬃcult simulator courses in healthy drivers (Eoh et al., 2005).
The suppression of Alpha associated with benzodiazepine use
may be indicative of cognitive compensatory mechanisms being
activated, leaving fewer resources for coping with higher driving
demands when needed. Since increases in cognitive demand
are correlated with greater likelihoods of committing errors
(Fairclough et al., 2005), it is possible that the reduction in
Alpha due to benzodiazepine use may also serve as an indicator
for increased risk of driving errors. EEG Beta activity (13–
30 Hz) is of particular interest in relation to driving abilities;
as benzodiazepine use is associated with increased activity in
the parietal and central regions (i.e., motor cortex) as well as
in the bilateral frontal–temporal and temporal–occipital regions
(Hendler et al., 1980; Buchsbaum et al., 1985; Bond et al., 1992;
Staner et al., 2005). Because increased Beta activity across the
motor cortex is associated with a reduction in motor movements
(Baker, 2007), this could potentially be an indicator of a reduction
in driving-related psychomotor functioning.
In addition to EEG metrics, ECG metrics may also
be informative in assessing impairments associated with
benzodiazepine use. For example, research has shown that the
administration of a benzodiazepine elevates heart rate (HR;
Muzet et al., 1981; DiMicco, 1987; Ueda et al., 2013). This
ﬁnding could possibly be related to, and predictive of, the
impairments associated with this class of drug. HR variability
(HRV) may also be predictive of such impairments as its
quadratic relationship with the activation of the parasympathetic
nervous system (Goldberger et al., 2001) provides detail on
the autonomic nervous system’s functioning through the low
frequency/high frequency ratio (Camm et al., 1996; Sztajzel,
2004). In fact, research has shown promise for using this metric
to detect driving errors. For example, decreased HRV is related
to drowsiness while driving (Murata and Hiramatsu, 2008), as
well as increases in drowsiness related driving errors (Michail
et al., 2008). This class of drugs has been shown to reduce HRV
(Adinoﬀ et al., 1992; Agelink et al., 2002), which, in addition to
drowsiness, may also indicate impaired cognitive functioning. To
this end, research has shown that those with lower HRV show
decreased accuracy, and increased reaction times, on working
memory and vigilance tasks (Hansen et al., 2003). For these
reasons, ECG was also time-synced to the neurocognitive tasks.
In summary, these ﬁndings provide a foundation establishing
that the neurocognitive, physiological, and behavioral eﬀects of
benzodiazepines can both be measured and used to detect levels
of driving related impairment.
While there has been extensive research on the cognitive,
behavioral, and neurophysiological eﬀects of benzodiazepines,
research is needed on whether these impairments can be utilized
to predict and diﬀerentiate between who is safe to drive and
who is impaired due to benzodiazepine use. The variability
inherently associated with real-world, on-the-road assessments,
in addition to the risk for accidents, complicates the orchestration
of safe and controlled research studies of benzodiazepine-related
driving impairments. Innovations in virtual environments have
made driving simulators a highly valid alternative to on-the-
road assessments. Furthermore, driving simulator performance
has been shown to be related to, and predictive of, on-the-road
driving performance (Lee, 2003; Lew et al., 2005; De Winter
et al., 2009; Bédard et al., 2010). Therefore, a driving simulator
is the most eﬀective platform for conducting safe, controlled, and
reproducible studies on the eﬀects of CNS active drugs, such as
benzodiazepines, on driving performance.
The current study utilized such a platform to assess the
use of neurocognitive, physiological, and behavioral indicators
for predicting benzodiazepine-related impairment. Although
performance on laboratory-based cognitive tasks have previously
been shown to be related to Standard Deviation of Lateral
Position (SDLP; Verster et al., 2002), an indicator of driving
performance, these tasks, alone, have not been able to predict
much of the variability in SDLP (Verster and Roth, 2012).
By adding real-time neurophysiology to cognitive tasks, we
hypothesized that we would be able to predict variability
in simulated driving performance. Since simulated driving
performance predicts real-world driving, such ﬁndings would
not only demonstrate the promise for this alternative approach
for future research on this topic, but could also lead to further
validation of, and improvement upon, assessments for drugged
driving related impairments.
MATERIALS AND METHODS
Participants
A total of N = 24 participants were recruited and enrolled
following a two level screening process. Participants were
recruited through a database registry (n = 7000+) whereby
emails and phone calls were sent out to a randomized set of
individuals who met the pre-screening criteria. Additionally,
participants were recruited through emails sent to all 30000+
students/faculty associated with the University of Iowa. Prior
to any participant screening visits, an initial phone screen
was completed to increase the rate of participants passing the
screening visit. The phone screening involved a variety of yes or
no questions to determine preliminary eligibility.
If initially eligible, participants were required to come to
the National Advanced Driving Simulator facility (NADS) at
the University of Iowa’s Research Park (Coralville, IA, USA),
for an in-person screening visit, and to complete the informed
consent protocol prior to a more rigorous screening process.
Once enrolled, participants were then asked to complete the
following additional screening procedures: an initial urinalysis
drug screen to ensure they tested negative for all drugs, a
pregnancy screen (if female), a brief physical examination
of vital signs (including HR and blood pressure), and a
psychiatric exam using the Columbia-Suicide Severity Rating
Scale (C-SSRS). After successful completion of the physical
and psychiatric screening, an in-depth survey was administered
that included detailed demographics and questions about the
presence and extent of any preexisting abnormalities and/or
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mental health issues that may put the participant at a greater
risk for health complications, adverse drug reactions, or
interfere with the study procedures and results. All potential
enrollees were then asked to complete a brief (5–8 min) drive
in the simulator to assess for the propensity of simulator
sickness and to familiarize them with the operation of the
simulator. Following the drive, a wellness questionnaire was
administered to determine their individual risk of simulator
sickness; those scoring at high risk were removed from further
participation.
A total of n= 19 participants were selected for the analysis for
this study out of the originally qualiﬁed N = 24. The exclusions
were due to: (a) having poor EEG and/or ECG data quality
(<80% good data) (n = 1); (b) Simulator Sickness Questionnaire
indicating increased proneness to simulator sickness (n = 1); (c)
testing positive for non-approved drug within their system on
orientation visit (n = 2); and (d) failure to comply with study
protocol (n = 1). The ﬁnal dataset (n = 19) was comprised
of 31.6% females with 94.7% of the participants identifying as
Caucasian. This dataset had a mean age of 25.3 yr (range: 18–
38 year), a mean weight of 81.19 kg (SD: 12.85 kg), and a mean
height of 176.64 cm (SD: 15.85 cm).
All participants received monetary compensation for taking
part in the current study. Participants were paid at the end
of their last visit. Payment schedules went as follows: $25 for
Orientation, $115 for ﬁrst experimental session, and $135 for
the second experimental session. If a participant was unable to
complete the experiment, they were paid for any past visits and
additional $20/h for the time they completed in their last session.
All procedures were reviewed by the University of Iowa IRB, and
approved prior to study implementation.
Equipment/Materials
Self-report Tools
Three self-report tools were used after ﬁnal screening to (1)
screen out those at higher risk of simulation sickness (Simulator
Sickness Questionnaire; Kennedy et al., 1993); (2) conﬁrm
compliance with sleep and caﬀeine intake requirements (Intake
Survey; Brown et al., 2014); and (3) to assess general sleepiness
prior to drug administration (Stanford Sleepiness Scale; Johnson
et al., 1990). As the class of benzodiazepine drugs are associated
with increased fatigue, and the eﬀects on driving are thought to
stem, in part, to the fatigue related eﬀects, sleepiness assessment is
essential to ensure that the eﬀects of the drug are being measured,
rather than some unrelated fatigue issues.
Psychophysiology
EEG and ECG were acquired using the B-Alert R© X10 wireless
sensor headset (Advanced Brain Monitoring, Inc, Carlsbad, CA,
USA). This system had nine referential EEG channels located
according to the International 10–20 system at Fz, F3, F4, Cz,
C3, C4, POz, P3, and P4 and an auxiliary channel for ECG.
Linked reference electrodes were located behind each ear on
the mastoid bone. ECG electrodes were placed on the right
clavicle and the lower left rib. Data were sampled at 256 Hz
with a high band pass at 0.1 Hz and a low band pass, ﬁfth
order ﬁlter, at 100 Hz obtained digitally with Sigma-Delta
A/D converters. Data was broadcasted to an iOS-Compatible
Bluetooth transmitter using a wired conﬁguration, which then
transmitted the data wirelessly via Bluetooth to a host iOS device,
where acquisition software then stored the psychophysiological
data. The proprietary acquisition software also included artifact
decontamination algorithms for eye blink, muscle movement,
and environmental/electrical interference such as spikes and
saturations. After obtaining head measurements, the B-Alert R©
X10 wireless sensor headset was placed on the subject’s head, with
accompanying leads, and the impedance was tested until optimal
connectivity was achieved (<40.0 ks) prior to each of the three
data collection sessions.
Drive Simulator
The NADS miniSimTM Research Driving Simulator is a PC-
based research driving simulator with powerful scenario editing
and data acquisition capabilities that is based on over a decade
of research and driving simulation experience at the University
of Iowa’s National Advanced Driving Simulator (NADS). The
miniSimTM can be conﬁgured a variety of ways, including
single and multi-screen displays and desktop, 1/4-cab and 1/2 cab
conﬁgurations.
miniSim™ Data Collection Mode
The miniSimTM data acquisition system (DAQ) runs every time
a scenario is ran. The DAQ collects well over 100 variables for
post-processing; the Runtime Measures Evaluation functionality
oﬀers the researcher the option of obtaining measures from
the simulator immediately when the drive ends. Among these
variables are: Mean Lane Position, Standard Deviation of
Lane Position, Lane Departure, Standard Deviation of Steering
Wheel Angle, Steering Entropy, Steering Bandwidth, Lateral
Acceleration, Speed, Standard Deviation of Speed, Longitudinal
Acceleration, and other event speciﬁc measures. The measures
are reported for the entire drive. The user has total control in
deﬁning the start and end points of each event through the
scenario. For the analyses presented herein, there is a focus
on assessing Standard Deviation of Lane Position and Lane
Departures, as these metrics have shown promise in assessing
benzodiazepine-related impairments in previous studies. The
Standard Deviation of Lane Position is a combination of
averaging the variability in lane position across events and road
conditions, as well as the variability of speed across these events
(25–70 mph), and variability and driving conditions, while Lane
Departure refers to any time a wheel crossed over a lane line.
A total of three scenarios were programmed with consistent
events, and comparable diﬃculty, that included three Road type
segments: Rural, Urban, and Highway; with 6–10 events in each
segment. These scenarios were used equally, counterbalanced
across participants so that each received two (1 per drive). The
events are shown in Table 1.
Doses, Administration, and Design
Drugs
The study was conducted according to a double blind, placebo-
controlled, within subject, cross-over design. Two dosing
conditions existed: (1) administration of the benzodiazepine and
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(2) administration of a matched placebo. In order to provide
an identical dose, both conditions delivered an encapsulated,
identical in size (size 0) and similar in weight and appearance
(non-labeled, colored-blue and opaque), pill. The benzodiazepine
[1 mg instant release (IR) alprazolam] was manufactured by
Mylan R© and obtained through the University of Iowa Hospitals
and Clinics, under the DEA license of the Principal Investigator
(PI). A low dose of 1mg IR alprazolam was chosen because
several studies have found that this dose signiﬁcantly impairs
cognitive function and driving performance (Leufkens et al.,
2007; Dassanayake et al., 2011). The placebo (lactose) was
supplied as lactose monohydrate NF (National Formulary),
manufactured by Professional Compounding Centers of America
(PCCA). The placebo and the benzodiazepine were encapsulated
at the University of Iowa College of Pharmacy by blinded outer
capsules, made by Gallipot Inc., to ensure that administration of
the drug/placebo remained blind.
Neurocognitive Assessment Tasks (M-AMP)
Participants were required to complete the Mobile Alertness
Memory Proﬁle (M-AMP) as part of the study protocol at
three time points (orientation and as part of each of the
two experimental sessions), with synchronized psychophysiology
TABLE 1 | Road type segments and events.
Road type
segment
Event Description
Rural TurnOffRamp Transition from off-ramp to rural road
Rural Lighted Straight section of lighted rural road
Rural TransToDark Partially lighted rural road
Rural Dark Mixture of curves and tangents without
environmental lighting
Rural TransToGravel Transition from dark rural to gravel
Rural Gravel Rural gravel road with curves
Rural Driveway Gravel curve past a house and driveway
Rural GravelExtension Rural gravel road with curves
Rural GravelTransToRural Transition to paved rural road from gravel
Rural RuralStraight Ten minute rural tangent
Highway OnRamp Transition from urban to interstate via ramp
Highway MergeOn Transition from ramp to interstate
Highway Interstate Divided highway with traffic in same
direction
Highway MergingTraffic Interchange with traffic that merges and
forces driver to change lanes
Highway InterstateCurves Divided highway with curves
Highway ExitRamp Transition from interstate via ramp
Urban Pullout Entering driving lane from parking spot
Urban Urban General Urban environment with curves and
tangents
Urban Green Light Intersection with green light
Urban Yellow Intersection with light that turns yellow as
driver approaches
Urban Left Intersection with left turn across traffic
Urban UrbanCurves Less dense urban environment with curves
Urban UrbanEarly Urban environment with curves and
tangents
from the B-Alert X10. Using an Apple iPad R© (fourth generation),
the tasks that were completed included:
3-Choice Active Vigilance Task (3CVT)
The three choice active vigilance task (3CVT) is a 20 min long
task that requires participants to discriminate one target (70%
occurrence) from two non-target (30% occurrence) geometric
shapes. Each stimulus was presented for a duration of 200ms. The
inter-stimulus interval was variable and changed for each quartile
of the task: 1–3 s for the 1st quartile, 1–6 s for the second and
third quartiles, and 1–10 s for the last quartile. Participants were
instructed to respond as quickly as possible to each stimulus by
selecting the left arrow for target stimuli and the right arrow for
non-target stimuli. A training period was provided prior to the
beginning of the task in order to minimize practice eﬀects.
Visual Psycho-Vigilance Task (VPVT) and Auditory
Psycho-Vigilance Task (APVT)
The Visual Psycho-Vigilance Task (VPVT) and Auditory Psycho-
Vigilance Task (APVT) were passive vigilance tasks that lasted
5 min each. The VPVT repeatedly presented a 10 cm circular
target image for a duration of 200 ms. The target image was
presented every 2 s in the center of the computer monitor,
requiring the participant to respond to image onset by pressing
the spacebar. The APVT consisted of an auditory tone that was
played every 2 s, requiring the participant to respond to auditory
onset by pressing the spacebar.
Standard Image Recognition (SIR)
The Standard Image Recognition (SIR) task was used to evaluate
attention and short-term memory and takes 6 minutes to
complete. The IR task included both training and testing periods.
During the training period, participants were asked to memorize
a series of 20 target images that were presented twice per image.
To ensure the participant was attending to the target images, they
were required to respond to each image by pressing the left arrow
key. In the testing period, the participants were then asked to
identify the target images (selecting the left arrow key for targets
or right arrow key for non-target, as with the 3CVT) in a ﬁeld of
100 total images (20 targets/80 non-target). This task is capable of
employing several diﬀerent categories of images (animals, food,
sports, and travel); the animals category is always used unless
the participant must restart the task, in which case images from
a diﬀerent category are displayed. These images were used in a
counterbalanced order across participants to ensure that there
were no carryover eﬀects over time for each participants.
Protocol
Eligible participants completed a total of three visits: orientation
and two experimental sessions that were identical in procedure,
diﬀering only in dosing condition.
Orientation
After completion of the screener and determination of ﬁnal
eligibility, participants were asked to complete an initial
M-AMP with synchronized psychophysiology. The 45-min
session consisted of the 3CVT (20 min), VPVT (5 min), APVT
(5 min), and SIR (6 min), as well as practice and transition
periods. These tasks began prior to 11:00 AM in order to ensure
Frontiers in Psychology | www.frontiersin.org 5 November 2015 | Volume 6 | Article 1799
Stone et al. Assessment of Benzodiazepine Impaired Driving
that diurnal variation in the EEG signal did not confound results
throughout the study. If participants were unable to begin these
tasks prior to 11:00 AM, a second orientation visit was scheduled.
The ﬁrst experimental sessions were scheduled upon completion
of the M-AMP.
Experimental Sessions
The two experimental study visits were scheduled at a minimum
of 5 days apart in order to allow for an adequate drug wash-
out period between study visits. Experimental sessions lasted
approximately 5–6 h and started at either 7:00 AM or 8:00 AM.
Upon arrival for a study visit the subject was required to provide
a urine specimen for drug screening and, if female, a pregnancy
test. In the case of a positive drug screen, the subject was taken
home and the visit was rescheduled for a later date, taking into
account the time it takes for the drug to clear the participant’s
system. After urinalysis, the capsule (drug or placebo) was
administered to participants accompanied with a full glass of
water. Upon swallowing the capsule, a two-hour waiting period
began. During this two hour waiting period, to allow for peak
activity of the study drug, participants remained seated and
relaxed in the subject prep room. Subjects were allowed to listen
to music, read, and/or browse the internet, however continuous
monitoring ensured that they did not fall asleep. Immediately
following this waiting period, the M-AMP was administered to
assess neurocognitive functioning. All M-AMP sessions began by
11:00 AM to ensure limited diurnal variation in the EEG signal.
Once participants completed this test battery, they were moved
into the miniSimTM room and began their drive.
The study drive consisted of four simulated nighttime
segments. Each segment lasted approximately 10 minutes and
included urban, freeway, and rural roadways that included a
mixture of road geometries and speeds. It should be noted
that this drive was designed to provide a cross section of
driving environments to assess how performance varies as driving
context varies and diﬀers (Lee et al., 2010) substantially from
traditional simulated road tests utilizing only straight roads at a
constant speed. Therefore, as the SDLP values are considered, it
is important to note some diﬀerences relative to other published
data. Most published data uses a common driving environment
including straight roads at a constant speed, but the research
presented herein involves a diverse environment containing a
variety of driving situations. The result of this is that many
of our SDLP values are not directly comparable to other
methodologies. Lastly, participants completed the Simulator
Sickness Questionnaire in response to their experience during the
study drive.
The second experimental session was scheduled at the end of
the ﬁrst session. After each visit, participants were taken home by
a taxi service to ensure they were not driving under any potential
inﬂuence due to the study procedures.
Statistics
One way ANOVAs (drug condition) were conducted for the drive
metrics of SDLP and Lane Departures (LnDPs), both for the
overall drive and for each event of the drive (i.e., Urban Yellow
Light, Rural gravel Extension); Bonferroni adjustments were
made for multiple comparisons. Our goal is not to identify drug
use, but rather the impairments associated with drug use. For
this reason, we stratiﬁed participants/sessions into “impaired”
vs. “unimpaired” based on performance on SDLP and LnDPs.
From this stratiﬁcation we found that n = 1 placebo session was
impaired, and n = 6 drug use sessions were unimpaired. We
removed the placebo confounded session from further analysis,
and included the “drug-unimpaired” in the unimpaired category
after an initial assessment showed no signiﬁcant diﬀerences
between these sessions and the placebo-unimpaired group.
We then conducted one-way ANOVAs on the M-AMP data
for performance and neurophysiologic metrics: EEG bandwidths,
EEG wavelets, HR, and HR Variability, based on impairment.
Tukey’s range test for pairwise comparisons were used for post
hoc tests.
In order to begin to determine the predictive value of the
M-AMP on driving impairment, we regressed the M-AMP
data onto the SDLP and LnDP, by M-AMP task (i.e., we
regressed the 3CVT metrics separate from the VPVT, APVT,
and SIR metrics). We performed several forward step-wise
regressions to identify the predictive power of performance
and neurophysiological metrics for each of the aforementioned
tasks. During the step-wise regression, in each step, a set of
F-tests were performed as the selection criteria to determine
the explanatory power of variables and to select which
variables to include in the model. The metrics identiﬁed by
the regressions were then used in a cross-validated 2-Class
discriminate function analysis by “impairment” status (based on
SDLP and LnDP as noted) to identify the potential predictive
power of the neurocognitive assessment in predicting driving
impairment.
To further evaluate classiﬁcation accuracy, we applied a
machine learning approach (boosting) to the dataset. The
boosting algorithm, AdaBoost (Freund and Schapire, 1997; Viola
and Jones, 2001) combines multiple weak learners into a single
strong classiﬁer. Each weak learner is a simple decision stump
that depends only on a single variable from the input training
vectors. The ﬁnal prediction rule is a weighted majority vote
of weak learners in which the weight of each weak learner is a
function of its accuracy. The error of the boosted classiﬁer drops
exponentially when the weak learners’ accuracy is slightly better
than random guessing. AdaBoost maintains a set of weights over
the training samples to focus the training process on samples
that are misclassiﬁed. This is done by increasing the weights of
the training samples that are misclassiﬁed and decreasing the
weights of the training samples that are correctly classiﬁed in each
boosting round.
RESULTS
One Way ANOVAs
Drive
A one-way ANOVA was conducted in order to investigate the
eﬀects of the drug on SDLP throughout the driving session
which revealed that those who were given the benzodiazepine
(M = 41.76 cm, SD = 6.10) had signiﬁcantly greater SDLP
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FIGURE 1 | (A) ANOVA results of overall SDLP for Placebo versus Drug; (B) ANOVA results of overall LnDP for Placebo versus Drug (∗p < 0.05).
than those who were given the placebo (M = 37.49 cm,
SD = 4.27), F(1,33) = 6.12, p < 0.05. For comparison, the
relatively straight portion of the urban drive, when considered
alone, showed the same pattern of eﬀects with those who were
given the benzodiazepine (M = 25.73 cm, SD = 9.16) having a
signiﬁcantly greater SDLP than those who were given the placebo
(M = 19.19 cm, SD = 8.49), F(1,18) = 6.02, p < 0.05. Since the
inability to maintain lane position is one of the cues oﬃcers use
to predict impairment due to intoxication (NHTSA, 1997), we
investigated LnDP as well. The one-way ANOVA on the sum
of LnDPs for the overall drive revealed a signiﬁcant diﬀerence
between drug conditions, F(1,33) = 10.11, p < 0.01, with the
benzodiazepine condition (M = 54.68, SD = 28.72) having
signiﬁcantly more LnDPs than placebo (M = 29.6, SD = 11.46).
These ﬁndings are shown in Figure 1.
In addition to overall drive eﬀects, ANOVAs were used
to examine the events within the drive, as some are more
sensitive to impaired driving than others, by design. For SDLP,
we found signiﬁcant diﬀerences between conditions for the
following events: Urban General F(1,33) = 4.27, p < 0.05;
Urban Green Light F(1,33) = 4.66, p < 0.05; Highway
Interstate F(1,33) = 10.24, p < 0.01; Rural Transition to Dark,
F(1,33) = 8.18, p < 0.01; and Rural Straight, F(1,33) = 12.81,
p < 0.001. These data are reported in Table 2 and shown in
Figure 2. For LnDPs, the following events revealed signiﬁcant
diﬀerences between the two conditions: Highway Interstate
F(1,33)= 6.36, p< 0.05; Rural Dark F(1,33)= 5.52, p< 0.05; and
Rural Straight F(1,33) = 14.24, p < 0.001 (see Table 2; Figure 2).
M-AMP Impairment
One way ANOVAs were conducted to detect signiﬁcant
diﬀerences in performance and neurophysiology between the
drug-impaired and unimpaired groups for all M-AMP tasks. The
two groups signiﬁcantly diﬀered on the following physiologic
metrics during the 3CVT: P3Gamma (25–40 Hz), F(1,33)= 4.22,
p < 0.05; and Midline Alpha Slow (Fz, Cz, Pz, and POz from 8
to 10 Hz), F(1,33) = 4.22, p < 0.05. For performance, we found
reaction time and reaction variability to be signiﬁcantly diﬀerent,
TABLE 2 | One way ANOVA – drive metrics.
Metric Road type
segment-event
Condition Mean
(cm)
Standard
deviation (cm)
SDLP Urban-general∗ Placebo 22.45 7.08
Drug 28.03 8.34
Urban-green light∗ Placebo 18.77 7.95
Drug 25.03 8.74
Highway-interstate∗∗ Placebo 45.5 6.4
Drug 56.27 11.71
Rural-transition to dark∗∗ Placebo 26.29 6.89
Drug 37.98 14.56
Rural-straight∗∗∗ Placebo 34.21 7.06
Drug 50.65 17.15
LnDP Highway-interstate∗ Placebo 9 4.5
Drug 13.84 6.26
Rural-dark∗ Placebo 4.07 2.94
Drug 7.58 5.16
Rural-straight∗∗∗ Placebo 4.81 4.68
Drug 16.79 11.92
∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001
including: overall correct response variability, F(1,33) = 5.07,
p < 0.05; variability in correct response to interference stimuli
during the ﬁrst quartile, F(1,33) = 4.45, p < 0.05; reaction times
for correct responses across all stimuli types during the fourth
quartile F(1,32) = 4.59, p < 0.05; and variability in correct
response reaction times across all stimuli types during the 4th
quartile, F(1,32) 4.67, p < 0.05. The mean and SD for these
ﬁndings are shown in Table 3.
Signiﬁcant diﬀerences based on impairment were found for
the other three tasks as well. For the VPVT, performance
diﬀerences were found between the two groups, with the drug-
impaired group having signiﬁcantly more missed responses
(M = 3.92, SD = 4.03) than the unimpaired group (M = 1.24,
SD = 2.17), F(1,28) = 5.52, p < 0.05 (no physiologic diﬀerences
were revealed). Similar to the performance diﬀerences observed
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FIGURE 2 | (A) ANOVA results of SDLP for road type-events; (B) ANOVA results of LnDP for road type-events (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001).
TABLE 3 | One way ANOVA – 3CVT data.
Metric Impairment group Mean Standard deviation
P3 Gamma (25–40 Hz) Unimpaired 2.44 0.40
Drug-impaired 2.20 0.19
Midline Alpha Slow (8–10 Hz) Unimpaired 2.95 0.26
Drug-impaired 3.19 0.41
Overall standard deviation of reaction time for correct-targets Unimpaired 0.15 0.06
Drug-impaired 0.20 0.06
Standard deviation of reaction times to interference stimuli (Q1) Unimpaired 0.10 0.04
Drug-impaired 0.13 0.05
Mean reaction time for correct-targets, quartile 4 Unimpaired 0.73 0.13
Drug-impaired 0.84 0.17
Standard deviation of reaction time for correct-targets, quartile 4 Unimpaired 0.16 0.06
Drug-impaired 0.25 0.19
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FIGURE 3 | Standard Deviation of Lateral Position (SDLP) variance explained by HR, EEG, and Performance metrics within the (A) 3CVT; (B) APVT;
and (C) SIR task.
TABLE 4 | Standard Deviation of Lateral Position (SDLP) regression
models.
Standard deviation in lane departures (SDLP)
Metric F Adj. R2
3C
V
T
Parietal hemispheric difference, Alpha (8–13 Hz) 6.19∗ 0.18
F4 Gamma (25–40 Hz) 4.06∗ 0.08
Standard deviation of reaction times to non-targets 4.6∗ 0.07
Heart rate (HR) 4.53∗ 0.06
Frontal hemispheric difference, Delta (1–3 Hz) 5.91∗ 0.07
POz Slow Theta (3–5 Hz) 6.04∗ 0.06
Reaction time to non-targets, quartile 4 6.09∗ 0.05
Incorrect non-target rate, quartile 1 3.3 0.02
Incorrect non-target rate, quartile 4 8.26∗∗ 0.04
Accuracy overall, quartile 4 3.84∗ 0.02
Overall Gamma (25–40 Hz) 5.77∗ 0.02
Overall hemispheric differences, Beta (13–30 Hz) 7.5∗ 0.02
Incorrect interference rate, quartile 4 5.57∗ 0.01
Accuracy non-target Rate, quartile 1 7.62∗ 0.01
A
P
V
T
Lapses, 6 s or longer 7.03∗ 0.18
Central hemispheric differences, Gamma
(25–40 Hz)
3.3∗ 0.07
Central hemispheric differences, Delta (1–3 Hz) 3.07∗ 0.06
Frontal hemispheric difference, Fast Alpha (10–13 Hz) 2.75 0.05
Lapses, 3 s or longer 4.5∗ 0.07
C4 Theta (3–7 Hz) 3.74 0.05
Cz Fast Alpha (10–13 Hz) 6.95∗ 0.08
Fz Delta (1–3 Hz) 4.2 0.04
C4 Sigma (12–15 Hz) 3.4 0.03
POz Gamma (25–40) 3.39 0.03
Central hemispheric differences, Alpha (8–13 Hz) 4.37∗ 0.03
Overall hemispheric differences, Delta (1–3 Hz) 3.91∗ 0.02
Parietal hemispheric difference, Sigma (12–15 Hz) 4.73∗ 0.03
C4 Delta (1–3 Hz) 7.15∗ 0.03
F3 Gamma (25–40 Hz) 11.24∗∗ 0.03
S
IR
Frontal hemispheric difference, Slow Alpha (8–10 Hz) 7.42∗ 0.19
Incorrect target rate 4.94∗ 0.11
Frontal hemispheric difference, Beta (13–30 Hz) 2.37 0.05
Central hemispheric differences, Beta (13–30 Hz) 4.92∗ 0.09
∗p < 0.05; ∗∗p < 0.01; Adj. R2 = adjusted R2 value of the model when the variable
was entered into the model.
for the VPVT, the APVT showed signiﬁcant diﬀerences onmissed
responses between groups with the drug-impaired group missing
more responses (M = 8.43, SD = 7.94) than the unimpaired
group (M = 1.32, SD = 2.87), F(1,34) = 14.82, p < 0.001.
In addition, during the APVT, the drug-impaired group had
signiﬁcantly more lapses (failure to respond for 3 s or longer,
M = 5.5, SD = 5.17) than the unimpaired group (M = 0.5,
SD = 1.19), F(1,34) = 19.29, p < 0.001. Neurophysiological
diﬀerences for the APVT revealed that overall Central Theta
(C3, Cz, C4; 3–7 Hz) was higher in the drug-impaired group
(M = 3.43, SD = 0.46) in comparison to the unimpaired
group (M = 3.19, SD = 0.23), F(1,34) = 4.25, p < 0.05.
During the SIR task, the drug-impaired group also showed
greater variability in reaction times (M = 0.18, SD = 0.05)
compared to the unimpaired group (M = 0.13, SD = 0.05),
F(1,33) = 11.23, p < 0.01, but no signiﬁcant diﬀerences in
accuracy or neurophysiology were found.
Forward Step Wise Regression
As individual M-AMP neurophysiologic and performance
metrics were not substantially informative in identifying
impairment, we explored whether the combination of multiple
metrics could best predict impaired driving performance. To
this end, we applied a forward step-wise regression of the
M-AMP metrics within each M-AMP task onto SDLP and
LnDP. For SDLP, 3CVT metrics explained 70.9% of variance,
F(14,18) = 7.62, p < 0.05, primarily by hemispheric diﬀerences
in parietal Alpha (8–13 Hz) (17.5%) and frontal (F4) Gamma
(25–40 Hz, 8.0%). Overall, 70.9% of variance was explained
by: EEG metrics (42.3%), elevated HR (6.3%), and performance
(22.2%). In contrast, the VPVT metrics were not statistically
signiﬁcant in explaining SDLP variability. However, the APVT
metrics explained 79.9%, with lapses explaining the most
variability at 17.5%, and with EEG metrics making up the
remainder (55.4%), F(15,19) = 11.24, p < 0.01. Finally, SIR
metrics explained only 43.9% of SDLP variance, primarily with
hemispheric diﬀerences (32.8%) at the frontal (F3 and F4) and
central (C3 and C4) sites within Slow Alpha (8–10 Hz) and
Beta (13–30 Hz). Performance metrics made up the remainder
(11.1%), F(4,29) = 4.92, p < 0.05. These data are presented in
Table 4 and visualized in Figure 3.
For the LnDPs, the 3CVT metrics were the most explanatory,
at 92.3%, F(13,19) = 10.66, p < 0.01, that relied on hemispheric
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parietal (P3 and P4) diﬀerences in Gamma (25–40 Hz) (19.5%)
and HRV during the third quartile of the 3CVT (11.3%), with
other EEG metrics making up the majority (68.5%) of the
variance explained, and performance contributing 12.4%. Once
again, the VPVT had a statistically insigniﬁcant model and thus
was not valid in explaining variability in LnDPs. The APVT
metrics, again, had high explanatory value F(14,19) = 5.18,
p < 0.05, with EEG making up the majority of the metrics
(58.5%) at various locations and bandwidths. Similar to SDLP,
performance metrics within the APVT had a signiﬁcant
explanatory role (19.0%), relying primarily on lapses. HRV
metrics within the APVT, though small (2.31%), also contributed
to explaining lane departures, such that decreases in HRV were
associated with increases in the variance in lane departures.
Finally, the SIR metrics explained 63.3%; F(5,27) = 6.7, p < 0.05;
relying on hemispheric diﬀerences (48.5%) across Alpha, Sigma,
Beta, and Gamma bandwidths, as well as performance (14.8%).
These data are presented in Table 5 and visualized in Figure 4.
Discriminant Function Analysis (DFA)
In order to further determine if the variables found in the
regression analyses could identify impairment risk, we entered
these variables into a 2-class (drug-impaired/unimpaired) linear
discriminate function analyses. While highly preliminary, the
results are promising from the leave one out cross validation
(LOOCV) method. The function was identiﬁed using the
LOOCV method to examine the generalizability of the model.
LOOCV uses one observation from the N = 30–32 as the
validation data in order to use it as testing data for the validation
model, while the rest of the data is used as training data. This
process is then repeated for each observation in the dataset so
that each sample is used once as the validation data. This, in turn,
creates the function prediction from the regression variables. By
using the signiﬁcant variables from the 3CVT, APVT, and SIR
regressions on SDLP, this analysis resulted in models that were
63.1, 87.0, and 76.8% accurate, respectively. For the 3CVT and
SIR, only the ﬁrst four variables from the regression were used
because it was found that adding more variables actually reduced
accuracy of the model. However, for the APVT, 13 variables
were needed to obtain the aforementioned level of accuracy.
Using variables identiﬁed in the Lane departure regressions, we
also found promising predictive results of impairment. Again,
the VPVT could not predict impairment due to an insigniﬁcant
regression model. However, the 3CVT, APVT, and SIR oﬀered
promising predictive models that were 72.7, 73.4, and 77.0%
accurate, respectively, with 9, 17, and 6 variables.
Machine Learning Approach – Boosting
Recognizing that the series of regressions that provided the
variables to be used within the DFA has the propensity
of introducing a biased estimate of the population variance
accounted for, it is likely that the aforementioned models could
overﬁt the predictor variables due to the small sample size.
To account for this, an adaptive boosting approach, AdaBoost
(n = 20 boosting rounds) was also applied to the dataset in a
leave-one-out cross-validation manner. This approach aims to
identify the strong boosted classiﬁer that predicts impairment
TABLE 5 | LnDP regression models.
Lane departures (LnDPs)
Metric F Adj. R2
3C
V
T
Parietal hemispheric difference, Gamma (25–40 Hz) 6.81∗ 0.2
HRV, quartile 3 4.46∗ 0.11
F4 Delta (1–3 Hz) 4.24∗ 0.1
F4 Slow Theta (3–5 Hz) 13.52∗∗ 0.21
Standard deviation of reaction times to Targets,
quartile 3
5.72∗ 0.07
Frontal hemispheric difference, Fast Theta (5–7 Hz) 10.31∗∗ 0.08
Midline (Fz, Cz, POz) Delta (1–3 Hz) 10.21∗∗ 0.05
P3 Fast ThetaF (5–7 Hz) 6.17∗ 0.03
Reaction time to non-targets, quartile 4 3.31 0.01
Reaction time to non-targets, quartile 2 7.52∗ 0.02
Parietal hemispheric difference, Alpha (8–13 Hz) 10.1∗∗ 0.02
Frontal (Fz, F3, F4) Fast Theta (5–7 Hz) 7.87∗ 0.01
Reaction time to interference stimuli, quartile 3 7.73∗ 0.01
A
P
V
T
Lapses, 6 s or longer 7.53∗∗ 0.19
F3 Gamma (25–40 Hz) 7.54∗∗ 0.16
Central hemispheric differences, Sigma (12–15 Hz) 7.45∗ 0.13
Frontal hemispheric difference, Fast Alpha (10–13 Hz) 2.51 0.04
F3 Delta (1–3 Hz) 4.38∗ 0.06
Cz Fast Theta (5–7 Hz) 2.9 0.03
C4 Delta (1–3 Hz) 3.18 0.03
Central hemispheric differences, Alpha (8–13 Hz) 5.91∗ 0.05
Central hemispheric differences, Beta (13–30 Hz) 5.1∗ 0.04
P3 Gamma (25–40 Hz) 3.1 0.02
Parietal hemispheric difference, Sigma (12–15 Hz) 2.25 0.01
Parietal (Pz, P3, P4) Fast Alpha (10–13 Hz) 3.15 0.02
C4 Gamma (25–40 Hz) 2.63 0.01
HRV 5.18∗ 0.02
S
IR
Frontal hemispheric difference, Slow Alpha (8–10 Hz) 6.95∗ 0.18
Incorrect target rate 6.66∗ 0.15
Overall hemispheric differences, Beta (13–30 Hz) 5.69∗ 0.11
POz Gamma (25–40 Hz) 6.41∗ 0.1
Overall hemispheric differences, Sigma (12–15 Hz) 6.7∗ 0.09
∗p < 0.05; ∗∗p < 0.01; Adj. R2 = adjusted R2 value of the model when the variable
was entered into the model.
risk (drug-impaired/unimpaired). Because the VPVT did not
have statistically signiﬁcant variables from the regressions, this
task was not incorporated into the boosting analysis. However,
the leave-one-out cross-validation of the remaining three tasks’
metrics were able to classify “impaired” vs. “unimpaired” based
on lane maintenance. Respectively, the 3CVT, APVT, and SIR
were found to have 58.06, 80.56, and 71.43% accuracy in
distinguishing such classiﬁcations.
DISCUSSION
Driving under the inﬂuence of drugs, especially benzodiazepines,
is not only hazardous for the driver, but everyone on the road
(Walsh et al., 2004; NHTSA, 2010; Dassanayake et al., 2011;
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FIGURE 4 | LnDP variance explained by HR, EEG, and Performance metrics within the (A) 3CVT; (B) APVT; and (C) SIR task.
Li et al., 2013; Brady and Li, 2014). DREs are least likely to
accurately recognize driving impairments due to nonalcoholic,
CNS depressants (including benzodiazepines), as compared
to impairment associated with other classes of drugs (Smith
et al., 2002). Validation of the existing criteria for determining
impaired driving, as well as the addition of new criteria, are
needed to assist DREs in conducting such assessments. Studies
have shown promise for utilizing cognitive, behavioral, and
neurophysiological signatures associated with benzodiazepine
use and impairment to aid in such investigations (Hendler et al.,
1980; O’Hanlon et al., 1982; Fernández-Guardiola et al., 1984;
Buchsbaum et al., 1985; Smiley and Moskowitz, 1986; Linnoila
et al., 1990; Bond et al., 1992; Van Laar et al., 1992; Kuitunen,
1994; Kožena et al., 1995; Suzuki et al., 1995; Münte et al.,
1996; Rush and Griﬃths, 1997; Bocca et al., 1999; Vanakoski
et al., 2000; Riba et al., 2001; Van Laar et al., 2001; Verster
et al., 2002; Barker et al., 2004; Eoh et al., 2005; Snyder et al.,
2005; Staner et al., 2005; Leufkens et al., 2007). Research has
even shown laboratory tasks to be directly related to SDLP, a
widely usedmeasure of driving performance (Verster et al., 2002).
However, these tasks alone cannot predict much of the variability
in driving performance (Verster and Roth, 2012). It is possible
that the addition of neurophysiology can help explain more of
this variance. Therefore, the current study sought to determine
whether all three classes of correlates could be leveraged as a
new approach for validating and suggesting improvements to the
current DRE evaluations.
The current ﬁndings, in agreement with previous work,
indicate that SDLP and LnDP are good indicators of impairment
and that the observation of poor lane position maintenance
provides justiﬁcation for conducting a DRE evaluation
(O’Hanlon et al., 1982; NHTSA, 1997; Bocca et al., 1999;
Van Laar et al., 2001; Verster et al., 2002; Leufkens et al., 2007).
Our analyses were able to pinpoint speciﬁc driving conditions
that make lane position maintenance especially diﬃcult for
those under the inﬂuence of benzodiazepines. These conditions
include open stretches of the interstate or highway, as well
as rural roadways. Thus, lane position diﬃculties under these
driving conditions may serve as particularly useful criteria
for oﬃcers to detect driving impairments associated with
benzodiazepines.
Though the results presented herein are in agreeance with past
literature, as previously mentioned, this dynamic environment
did introduce the likelihood for higher SDLP values. This
is important to note because three of the ﬁve statistically
signiﬁcant segments revealed from the ANOVAs were designed
to introduce more challenging maneuvers than observed in
previously published work. This is particularly true for the
interstate highway event. Although straight, this segment of the
driving course contains slower moving traﬃc, which causes the
drivers to circumnavigate the slower traﬃc by performing two
lane changes. These lane changes produce higher levels of SDLP
relative to the other events within the simulator. Similarly, the
rural events that yielded signiﬁcant diﬀerences in the ANOVA’s
also have elevated SDLP values. This is experienced in the Rural-
Transition to Dark segment due to the curvy nature of the
roadway and the short duration of time from dusk to dark while
on this roadway. The Rural-Straight portion of the drive also
introduces variances in SDLP values that are unlike those of past
studies. Even though this segment is straight, SDLP is elevated
due to the changes in participant’s alertness/wakefulness as this
is one of the last segments of the drive. Prior work has yielded
similar results; Brown et al. (2014) used this same scenario and
showed that even during daytime drives, sleepiness increased, as
measured by the Stanford Sleepiness Scale, over the course of the
drive and SDLP was elevated relative to earlier in the drive. These
three events have been speciﬁcally included in this evaluation due
to the fact that they represent more challenging environments.
Therefore, they are more likely to highlight, and be sensitive to,
drug eﬀects despite not conforming to the typical environments
in which they have been historically reported. On the other
hand, the other two statistically signiﬁcant segments revealed
within the SDLP ANOVAs have values similar to previously
suggested guidelines (Brookhuis et al., 2003). While the urban
general section does contain a portion where the roadway is
slightly curved, the urban green light segment is similar to more
commonly used driving simulator environments and may best
serve as a direct comparison to past literature. The fact that the
urban green light segment is both environmentally similar to
past literature and yields similar SDLP values suggests that the
performance of participants in both conditions are comparable
to that of those reported in previous studies.
The current study expanded on the ﬁndings that
benzodiazepines impair lane maintenance behaviors by
exploring the use of a neurocognitive assessment for explaining
the lane maintenance errors of drivers under the inﬂuence of
benzodiazepines. ANOVA results revealed behavioral ﬁndings
consistent with this ﬁeld of literature, such as increased reaction
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times during the 3CVT (Fernández-Guardiola et al., 1984; Suzuki
et al., 1995; Münte et al., 1996; Verster et al., 2002; Barker et al.,
2004; Snyder et al., 2005; Leufkens et al., 2007) and impaired
vigilance on the APVT and VPVT as indicated by the missed
responses and lapses (Kožena et al., 1995). However, we did not
ﬁnd any indications of memory impairment during the SIR. The
EEG ANOVA results indicated a reduction in parietal Gamma
(25–40 Hz), an elevation in Midline Alpha (8–10 Hz) during
the 3CVT, and Central Theta elevation during the APVT. The
central elevation in theta is consistent with ﬁndings that increases
in both Delta (1–3 Hz) and Theta (3–7 Hz) are positively
correlated with fatigue while driving and that benzodiazepines
are associated with increased fatigue (Lal and Craig, 2002;
Campagne et al., 2004). In contrast, the elevatedMidline Alpha is
inconsistent withmost studies that ﬁnd benzodiazepines decrease
Alpha (8–13 Hz) in the frontal, temporal, and occipital regions
(Buchsbaum et al., 1985; Bond et al., 1992; Staner et al., 2005).
However, suppression of Alpha can also be an adaptive response
to increasing simulation diﬃculty, indicating that a failure to
suppress Alpha may be a sign of failure to adapt by those under
the inﬂuence of a benzodiazepine (Eoh et al., 2005).
The regression and discriminate function analyses are more
consistent with prior work indicating that Beta (Hendler et al.,
1980; Buchsbaum et al., 1985; Bond et al., 1992; Staner et al.,
2005), Frontal Delta (Buchsbaum et al., 1985; Staner et al.,
2005), and Alpha over multiple regions (Buchsbaum et al.,
1985; Bond et al., 1992; Staner et al., 2005) are associated with
benzodiazepine use. These ﬁndings also support the combination
of neurophysiology and performance in objectively assessing
and predicting impairment due to benzodiazepines, as past
studies failed to explain variability in SDLP using performance
metrics alone (Verster and Roth, 2012). To this end, the
current data indicate that combining performance metrics with
neurophysiology can explain up to 79.9% of the variance in SDLP
using APVTmetrics alone. However, the combination of metrics
within the regression analyses indicated that HR measures were
only signiﬁcant in explaining SDLP impairment within the 3CVT,
and not in any of the other tasks. Herein, results were in agreeance
with past literature, as HR during this task did increase as a
result of the benzodiazepine (Muzet et al., 1981; DiMicco, 1987;
Ueda et al., 2013) and was a signiﬁcant predictor of SDLP. This
approach yielded promising results for lane departures as well. In
comparison to the SDLP results, we were able to explain more
of the variance in lane departures with 3CVT metrics, explaining
92% of the variance in this measure. Similar to the results seen
for SDLP, HRV was shown to have a signiﬁcant explanatory
power within the 3CVT task for assessment of lane departures.
HRV measures showed signiﬁcant explanatory power within the
APVT task as well, which supports the results from previous
studies showing that benzodiazepines decrease HRV (Adinoﬀ
et al., 1992; Agelink et al., 2002), decreases in HRV are related
to increases in drowsiness related driving errors (Michail et al.,
2008), and that decreased HRV is associated with cognitive and
behavioral impairments (Hansen et al., 2003). The discriminate
function classiﬁcation and boosting results were even more
promising, respectively, showing up to 87 and 80% accuracy in
identifying impairment likelihood based on neurophysiology and
performance within cognitive tasks. While preliminary, and in
need of replication in larger conﬁrmatory studies, these results
indicate the promise of this approach as a way for researchers
to gain further insight into the correlates of drug impaired
driving and consequently aid in the optimization of assessments
of benzodiazepine impaired driving.
While promising, this study does have limitations that should
be taken into account when interpreting our results. The
simulated environment utilized herein contains more diverse
driving scenarios than that of previous studies in order to
more closely resemble real-world driving. While results from
this design may have greater external validity, they do not
easily lend to comparisons with past ﬁndings. Future studies
utilizing the current approach could employ both types of driving
environments in order to enable such comparisons. In regards to
demographics, themajority of participants were youngmales, just
as most drugged drivers are also young males (Lacey et al., 2009).
This approach requires validation across genders and age groups
to determine whether the models will generalize across a larger
population. Additionally, we utilized a within subject design (to
reduce individual diﬀerences across conditions), but with the
small sample size, this may lead to an even greater likelihood
of overﬁtting the regression and discriminant function analyses.
Future research is needed to verify whether these ﬁndings can be
replicated with a larger sample size. Replication and expansion
of our design is also necessary in terms of dosing levels. Since
participants were only dosed with 1 mg of alprazolam in the
current study, our ﬁndings may only represent deﬁcits associated
with moderate to low doses of this benzodiazepine. A dose-
response study should be conducted to verify whether these
same correlates can predict, and classify, driving impairment
due to a range of dosing levels and to reveal whether other
correlates may better explain variances in performance due to
a wide range of doses. Other benzodiazepines, as well as an
array of CNS depressants outside of the benzodiazepine class,
should also be examined to determine if the eﬀects found
within this study are limited to alprazolam, or are true for all
benzodiazepines and CNS depressants. Furthermore, conditions
that are known to interact with CNS depressant use, such
as sleep deprivation and alcohol use, should be examined to
see how their interactions aﬀect driving impairment. Future
studies should expand on these ﬁndings to include broader
demographic diversity, greater sample size, dose response,
administration of diﬀerent benzodiazepines, and the use of other
types of CNS depressants. Taking these suggested limitations and
improvements into consideration, future studies should target a
means of taking the research beyond the scope of a simulated
environment in order to better provide the much needed support
for law enforcement in ensuring public health and safety for all
drivers.
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